CEO outlines commercialization plans and pipeline milestones
Daré Bioscience management outlined its shift from development-stage to commercial-stage in a Virtual Investor CEO Connect interview.
CEO Sabrina Martucci Johnson highlighted the launch of Flora Sync LF5, with DARE to PLAY Sildenafil Cream positioned as the next revenue driver.
Plans center on building a scalable commercial infrastructure to support multiple products, with emphasis on customer acquisition, provider engagement, and market access.
Ovaprene posted positive interim Phase 3 results, with DARE-HPV advancing into Phase 2.
Johnson flagged potential value catalysts over the next 12-18 months tied to commercialization progress and clinical milestones.
DARE•
